STOCK TITAN
  1. Home
  2. Sec-filings
  3. TNDM
  4. [8-K] TANDEM DIABETES CARE INC Reports Material Event

Tandem Diabetes (NASDAQ: TNDM) to terminate EVP & Chief Commercial Officer

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Tandem Diabetes Care, Inc. reported that on May 11, 2026, Executive Vice President and Chief Commercial Officer Mark Novara was notified that his employment is being terminated without cause. His last day with the company is scheduled for May 18, 2026. The company stated that its strategy and 2026 goals remain unchanged.

Positive

  • None.

Negative

  • Departure of key commercial executive: The Executive Vice President and Chief Commercial Officer, Mark Novara, is being terminated without cause, effective May 18, 2026, which may affect commercial leadership continuity.

Insights

Key commercial executive terminated, company maintains existing strategy.

Tandem Diabetes Care is removing its Executive Vice President and Chief Commercial Officer, Mark Novara, effective May 18, 2026, following notice on May 11, 2026. The filing states the termination is "without cause," which typically refers to non-misconduct reasons under employment agreements.

Leadership changes at this level can affect commercial execution, sales momentum, and customer relationships, especially in competitive medical device markets. However, the company explicitly notes that its strategy and 2026 goals remain unchanged, signaling that this move is positioned as organizational rather than strategic.

Future disclosures in company filings may clarify how commercial responsibilities are reassigned and whether any new leadership appointments follow this departure. The impact on commercial performance will become clearer as the company reports subsequent operating results for periods after May 18, 2026.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Notification date May 11, 2026 Date Mark Novara was notified of termination
Last day of employment May 18, 2026 Scheduled end of Mark Novara’s employment
Form type Form 8-K Current report under the Exchange Act
Item referenced Item 5.02 Departure of certain officers and related matters
terminated without cause financial
"was notified that his employment with the Company is being terminated without cause."
Executive Vice President and Chief Commercial Officer financial
"Mark Novara, the Executive Vice President and Chief Commercial Officer of Tandem Diabetes Care, Inc."
Item 5.02 regulatory
"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers."
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

What executive change did Tandem Diabetes Care (TNDM) disclose in this 8-K?
Tandem Diabetes Care disclosed that Executive Vice President and Chief Commercial Officer Mark Novara is being terminated without cause. He was notified on May 11, 2026, and his last day of employment is scheduled for May 18, 2026.

When is Mark Novara’s last day at Tandem Diabetes Care (TNDM)?
Mark Novara’s last day of employment at Tandem Diabetes Care is scheduled for May 18, 2026. He was notified of his termination without cause on May 11, 2026, according to the company’s current report on Form 8-K.

Was the termination of Tandem Diabetes Care’s EVP and CCO for cause?
No, the company states that Executive Vice President and Chief Commercial Officer Mark Novara is being terminated without cause. This language generally indicates the departure is not attributed to misconduct under the employment arrangement’s terms.

Does Tandem Diabetes Care (TNDM) plan to change its strategy after this leadership departure?
The company states that its strategy and 2026 goals remain unchanged following the termination of Executive Vice President and Chief Commercial Officer Mark Novara. This suggests the leadership change is not being presented as a shift in strategic direction.

What SEC item does this Tandem Diabetes Care (TNDM) filing relate to?
The filing relates to Item 5.02, which covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. It specifically addresses the termination of Executive Vice President and Chief Commercial Officer Mark Novara.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
0001438133FALSE00014381332026-05-112026-05-11


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

____________________________
FORM 8-K
____________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 11, 2026
____________________________
Tandem Diabetes Care, Inc.
(Exact name of registrant as specified in its charter)
____________________________
Delaware001-3618920-4327508
(State or other jurisdiction
of incorporation)		(Commission
File Number)		(I.R.S. Employer
 Identification No.)
12400 High Bluff Drive92130
San Diego California
(Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (858) 366-6900
N/A
(Former name or former address, if changed since last report)
____________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading SymbolName of Each Exchange on Which Registered
Common Stock, par value $0.001 per shareTNDMNASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
____________________________




Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 11, 2026, Mark Novara, the Executive Vice President and Chief Commercial Officer of Tandem Diabetes Care, Inc. (the “Company”), was notified that his employment with the Company is being terminated without cause. Mr. Novara’s last day of employment with the Company is scheduled to be May 18, 2026. The Company’s strategy and 2026 goals remain unchanged.


2


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Tandem Diabetes Care, Inc.
By:/s/ SHANNON M. HANSEN
Shannon M. Hansen
Executive Vice President, Chief Legal, Privacy & Compliance Officer and Secretary
Date: May 15, 2026
3

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents